US 2025/0145701 A1 · BISPECIFIC ANTIBODY AND APPLICATION THEREOF

Abstract

A VEGF-targeting VHH, a bispecific antibody targeting PD-1 and VEGF developed on the basis of the VHH, and an application thereof. The VHH has high stability, and has a plurality of excellent effects, such as ease of expression and purification. The constructed bispecific antibody targeting PD-1 and VEGF has high stability, can target enrichment in a high-expression VEGF tumor region, has good medicinal efficacy and safety, and has excellent treatment potential.

Claims29

Dependent claims

A bispecific antibody targeting programmed death receptor-1 (PD-1) and vascular endothelial growth factor (VEGF), comprising:

(a) a first binding functional region targeting PD-1;
and
(b) a second binding functional region targeting VEGF;
wherein,
the first binding functional region targeting PD-1 is an anti-PD-1 antibody or an antigen-binding fragment thereof;
and
the second binding functional region targeting VEGF comprises a variable domain of heavy chain of heavy-chain antibody (VHH) domain of complementarity-determining regions (CDRs) 1-3, wherein CDR1 comprises an amino acid sequence set forth in SEQ ID NO:
1, CDR2 comprises an amino acid sequence set forth in SEQ ID NO:
2 with or without one or two amino acid mutations, and CDR3 comprises an amino acid sequence set forth in SEQ ID NO:
3.

7 more elements

A VHH domain targeting VEGF, wherein the VHH domain comprises CDRs 1-3, wherein CDR1 comprises an amino acid sequence set forth in SEQ ID NO:

1, CDR2 comprises an amino acid sequence set forth in SEQ ID NO:
2 with or without one or two amino acid mutations, and CDR3 comprises an amino acid sequence set forth in SEQ ID NO:
3.

Dependencies are inferred from the claim text.

Bispecific antibody and application thereof

Life of this patent

Bispecific antibody and application thereof

Life of this patent

Abstract

Claims29